Core Viewpoint - Beijing Baipusi Biotechnology Co., Ltd. has shown a significant stock price increase of 5.07%, reaching 62.58 CNY per share, with a total market capitalization of 10.504 billion CNY as of October 9 [1] Company Overview - Baipusi was established on July 22, 2010, and went public on October 18, 2021. The company is located in Beijing Economic and Technological Development Zone [1] - The main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Fund Holdings - Tianhong Fund has a significant holding in Baipusi, with Tianhong Healthcare A (001558) owning 414,200 shares, representing 5.9% of the fund's net value, making it the seventh-largest holding [2] - The fund has realized a floating profit of approximately 1.251 million CNY from this investment [2] Fund Performance - Tianhong Healthcare A was established on June 30, 2015, with a current size of 251 million CNY. The fund has achieved a year-to-date return of 44.49%, ranking 1774 out of 8238 in its category [2] - Over the past year, the fund has returned 34.83%, ranking 2489 out of 8082, and since inception, it has delivered a return of 81.87% [2]
百普赛斯股价涨5.07%，天弘基金旗下1只基金重仓，持有41.42万股浮盈赚取125.1万元